Abstract
Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy are attributed to FIV-specific T-cell immunity. Findings from these studies are being used to define the prophylactic epitopes needed for an HIV-1 vaccine for humans.
Keywords: FIV, vaccine, AIDS, animal model
Current HIV Research
Title: Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines
Volume: 8 Issue: 1
Author(s): Janet K. Yamamoto, Missa P. Sanou, Jeffrey R. Abbott and James K. Coleman
Affiliation:
Keywords: FIV, vaccine, AIDS, animal model
Abstract: Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy are attributed to FIV-specific T-cell immunity. Findings from these studies are being used to define the prophylactic epitopes needed for an HIV-1 vaccine for humans.
Export Options
About this article
Cite this article as:
Yamamoto K. Janet, Sanou P. Missa, Abbott R. Jeffrey and Coleman K. James, Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines, Current HIV Research 2010; 8 (1) . https://dx.doi.org/10.2174/157016210790416361
DOI https://dx.doi.org/10.2174/157016210790416361 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Mass Spectrometry-Based Approaches for the Detection of Proteins of Staphylococcus Species
Infectious Disorders - Drug Targets Amyloid β Accumulation Assessed with <sup>11</sup>C-Pittsburgh Compound B PET and Postmortem Neuropathology
Current Alzheimer Research Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Detection of Cryptococcus neoformans Capsular Antigen in HIV-Infected Patients in the State of Para in the North of Brazil
Current HIV Research Viral Proteases as Targets for Drug Design
Current Pharmaceutical Design Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Subject Index to Volume 4
Current Drug Targets - Infectious Disorders CT and CT-guided Percutaneous Needle Biopsy in Diagnosis of Primary Pulmonary Cryptococcosis in Immunocompetent Patients
Current Medical Imaging Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Daptomycin: A Review of Properties, Clinical Use, Drug Delivery and Resistance
Mini-Reviews in Medicinal Chemistry Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Eight Stranded β -Barrel and Related Outer Membrane Proteins: Role in Bacterial Pathogenesis
Protein & Peptide Letters Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies
Current Drug Targets - Infectious Disorders Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry